Objective:To observe the effects of flavored Xiangsha Liujunzi decoction on inflammation in chem-otherapy patients with advanced colorectal cancer.Method:114 patients with advanced colorectal cancer were select-ed and divided into 57 cases in the control group and 57 cases in the observation group by simple randomization method.The control group was treated with corresponding chemotherapy regimen according to NCCN guidelines,and the observation group was treated with flavored Xiangsha Liujunzi decoction on the basis of chemotherapy regi-men.The differences in Piper Fatigue Scale(RPFS)score,Kasper(KPS)score,and Chinese medicine evidence score were compared between the two groups,and inflammatory factors were detected in the two groups,and the efficacy and safety of the two groups were compared.Results:Before treatment,the difference of RPFS score,KPS score and Chinese medicine evidence score in two groups was not statistically significant(P＞0.05).After treat-ment,the RPFS scores and Chinese medicine evidence scores were decreased,KPS scores were increased in the two groups,while the changes in the observation group were more significantly than in the control group(P＜0.05).The difference of inflammatory factors in the two groups before treatment was not statistically significant(P＞0.05).After treatment,tumour necrosis factor-α(TNF-α),interferon-γ(IFN-y),interleukin-10(IL-10)were de-creased and interleukin-4(IL-4)was increased in the observation group,with statistically significant differences(P＜0.05).The difference in the level of inflammatory factors before and after treatment in the control group was not statistically significant(P＞0.05).The total effective rate of the observation group was higher than that of the con-trol group(P＜0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P＜0.05).Conclusion:Flavored Xiangsha Liujunzi decoction can regulate the level of inflammatory factors and improve the therapeutic efficacy in patients undergoing chemother-apy advanced colorectal cancer.
NETL
NSTL
万方数据
